Skip to content
value.today

Amgen Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, 11.8% a year (statements).

%

US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt less cash at the end of FY2025 (statements); negative means more cash than debt.

What today's price assumes

A market value of $249.2 B means free cash flow growing 14.8% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.

Revenue grew 11.8% a year over the last three years.

Cash-flow value of the shares
$189.8 B
-24% against the market value
Value of the whole business
$235.2 B
before net debt
Value from after year 10
60%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →6.77%9.27%11.77%14.27%16.77%
7.92%-27%-7%+17%+46%+80%
8.92%-42%-26%-7%+16%+44%
9.92%-53%-40%-24%-5%+18%
10.92%-61%-50%-37%-21%-1%
11.92%-68%-58%-47%-33%-17%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Pharmaceutical: $141.5 B to $412.4 B, median $298.2 BPrice to salesPrice to sales of Pharmaceutical: $55.9 B to $246.2 B, median $127.2 BPrice to bookPrice to book of Pharmaceutical: $17.9 B to $69.0 B, median $35.2 BCash-flow value$0 M$111.3 B$222.7 B$334.0 B$445.4 BMarket value $249.2 B

Your own DCF model

A full discounted-cash-flow model of Amgen Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Pharmaceutical

Multiples of its companies with a market value at most 60 days old, times Amgen Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Amgen Inc.Applied toValue (25th to 75th)Companies
P/E18.4× / 38.7× / 53.5×26.5×net income $7.7 B$141.5 B to $412.4 B53
Price to sales1.5× / 3.5× / 6.7×6.4×revenue $36.8 B$55.9 B to $246.2 B68
Price to book2.1× / 4.1× / 8.0×28.8×book equity $8.7 B$17.9 B to $69.0 B62

Against its own history

Amgen Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

28.5×

Now above its median of 25.5×, in the top quarter of its range; range 17.1× to 40.7× over 30 months.

0×10×20×31×41×2020202120222023202420252026P/E 29×Median 25×

Price to sales

6.5×

Now above its median of 5.0×, in the top quarter of its range; range 4.2× to 6.5× over 30 months.

0×2×3×5×7×2020202120222023202420252026Price to sales 7×Median 5×

Price to book

28.8×

Now above its median of 25.9×, in the top quarter of its range; range 11.5× to 44.3× over 30 months.

0×11×22×33×44×2020202120222023202420252026Price to book 29×Median 26×

As of Oct 30, 2026

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$36.8 B$7.7 B$10.0 B$1.9 B$8.1 B$45.5 BSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$33.4 B$4.1 B$11.5 B$1.1 B$10.4 B$48.1 BSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$28.2 B$6.7 B$8.5 B$1.1 B$7.4 B$53.7 BSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$26.3 B$6.6 B$9.7 B$936 M$8.8 B$31.3 BSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$26.0 B$5.9 B$9.3 B$880 M$8.4 B$25.3 BSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$25.4 B$7.3 B$10.5 B$608 M$9.9 B$26.7 BSEC annual report (10-K, 20-F)